BioGaia ABCHIX:BIOGBS 100 Net Margin % is 21.32% as of Mar. 2026, which is 20% below its 10-year median of 26.59. GuruFocus rates CHIX:BIOGBS with a GF Score™ of 100/100 and a GF Value™ of kr129.06. The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, BioGaia AB ranks better than 88.6% on this metric.
Net margin is calculated as Net Income divided by its Revenue. BioGaia AB's Net Income for the
three
months ended in Mar. 2026 was kr79 Mil. BioGaia AB's Revenue for the
three
months ended in Mar. 2026 was kr373 Mil. Therefore, BioGaia AB's net margin for the quarter that ended in Mar. 2026 was 21.32%.
The historical rank and industry rank for BioGaia AB's Net Margin % or its related term are showing as below:
CHIX:BIOGBs'
s Net Margin % Range Over the Past 10 Years
Min: 21.5 Med: 26.59 Max: 42.56
Current: 21.5
CHIX:BIOGBs's Net Margin % is ranked better than 88.6% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CHIX:BIOGBs: 21.50
BioGaia AB (CHIX:BIOGBs) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioGaia AB Net Margin % Related Terms
BioGaia AB Net Margin % Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (CHIX:BIOGBS) has a Net Margin % of 21.32% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BioGaia AB and its competitors. This is 20% below median its historical median of 26.59. Over the past decade, BioGaia AB's Net Margin % has ranged from 21.50 to 42.56. According to the industry distribution chart, BioGaia AB ranks #109 out of 956 companies in the Drug Manufacturers industry, placing it in the top 11.4%.
Is BioGaia AB's Net Margin % too high?
BioGaia AB's current Net Margin % of 21.32% is 20% below median its 10-year median of 26.59. Over the past 10 years, this metric has ranged from a low of 21.50 to a high of 42.56. The Drug Manufacturers industry median Net Margin % is 5.56. BioGaia AB's value of 21.32% is 283.5% above this industry median. Based on the distribution chart, BioGaia AB ranks #109 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #109 out of 956 companies for Net Margin %. This places BioGaia AB in the top 11% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. BioGaia AB's value of 21.32% is 283.5% above this benchmark. Historically, BioGaia AB's own Net Margin % has ranged from 21.50 to 42.56 over the past decade. While the company's 10-year median is 26.59 vs. the industry median of 5.56, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Net Margin % of 21.32% is 283.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Net Margin % is 21.32%, which is 20% below median its own 10-year median of 26.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (CHIX:BIOGBS) has a current Net Margin % of 21.32%. The stock's GF Value™ is kr129.06, compared to a current price of kr120.20 — trading 6.9% below its estimated fair value. The current Net Margin % is 21.32%, which is 20% below median its 10-year median of 26.59 and 283.5% above the Drug Manufacturers industry median of 5.56. BioGaia AB's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioGaia AB (CHIX:BIOGBS), the current Net Margin % is 21.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (CHIX:BIOGBS) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of kr120.20 is trading 6.9% below its estimated GF Value™ of kr129.06.
Key valuation signals for CHIX:BIOGBS:
Net Margin %: 21.32% (20% below median its 10-year median of 26.59)
GF Value™: kr129.06 vs. price of kr120.20 (6.9% below fair value)
Industry Position: 283.5% above the Drug Manufacturers median (#109 of 956)
No single metric tells the full story. See the CHIX:BIOGBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for CHIX:BIOGBS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BIOGBS has been successfully added to your 
